Agoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone: a case report.
Agoraphobia
Mineralocorticoid
Panic Attacks
Primary aldosteronism
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
27 10 2023
27 10 2023
Historique:
received:
28
03
2023
accepted:
12
10
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
Primary aldosteronism (PA) is an adrenal gland disease, that induces increased secretion of the mineralocorticoid, aldosterone, resulting in symptoms such as hypertension. This study reports a patient with agoraphobia and panic attacks, associated with PA. This patient's psychiatric symptoms improved after treatment with eplerenone, a mineralocorticoid receptor antagonist. The patient was a 40-year-old female with agoraphobia, which refers to the irrational fear of situations that may cause anxiety, and panic attacks characterized by profuse sweating, palpitations, and generalized weakness. She was diagnosed with hypertension from PA. Subsequently, she received treatment with eplerenone, which improved her agoraphobia and panic attacks. There have been no previous reports on PA associated with agoraphobia and panic attacks that improved with pharmacotherapy. Patients with agoraphobia and panic attacks should be evaluated for PA. In patients with PA, pharmacotherapy with eplerenone should be considered.
Sections du résumé
BACKGROUND
Primary aldosteronism (PA) is an adrenal gland disease, that induces increased secretion of the mineralocorticoid, aldosterone, resulting in symptoms such as hypertension. This study reports a patient with agoraphobia and panic attacks, associated with PA. This patient's psychiatric symptoms improved after treatment with eplerenone, a mineralocorticoid receptor antagonist.
CASE PRESENTATION
The patient was a 40-year-old female with agoraphobia, which refers to the irrational fear of situations that may cause anxiety, and panic attacks characterized by profuse sweating, palpitations, and generalized weakness. She was diagnosed with hypertension from PA. Subsequently, she received treatment with eplerenone, which improved her agoraphobia and panic attacks.
CONCLUSIONS
There have been no previous reports on PA associated with agoraphobia and panic attacks that improved with pharmacotherapy. Patients with agoraphobia and panic attacks should be evaluated for PA. In patients with PA, pharmacotherapy with eplerenone should be considered.
Identifiants
pubmed: 37891534
doi: 10.1186/s12888-023-05275-w
pii: 10.1186/s12888-023-05275-w
pmc: PMC10604805
doi:
Substances chimiques
Eplerenone
6995V82D0B
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
787Informations de copyright
© 2023. The Author(s).
Références
J Clin Endocrinol Metab. 2011 Jun;96(6):E878-83
pubmed: 21389142
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
Am J Psychiatry. 2005 Jun;162(6):1226
pubmed: 15930081
J Clin Psychiatry. 1979 Aug;40(8):358-9
pubmed: 468762
Innov Clin Neurosci. 2019 Mar 1;16(3-4):19-21
pubmed: 31214479
Neuropharmacology. 2009 Feb;56(2):514-21
pubmed: 18977372
Horm Behav. 2008 Jun;54(1):90-7
pubmed: 18377905
J Psychopharmacol. 2010 May;24(5):779-86
pubmed: 19825909
Psychother Psychosom. 2006;75(5):327-30
pubmed: 16899970
J Psychiatr Res. 2000 Nov-Dec;34(6):383-92
pubmed: 11165305